Corbus Pharmaceuticals Holdings
Market Cap
US$322.6m
Last Updated
2019/10/19 00:37 UTC
Data Sources
Company Financials +
Executive Summary
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Snowflake
Fundamentals
Excellent balance sheet with limited growth.
Share Price & News
How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
7.3%
CRBP
3.1%
US Biotechs
1.8%
US Market
1 Year Return
-31.2%
CRBP
-7.9%
US Biotechs
7.3%
US Market
Return vs Industry: CRBP underperformed the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: CRBP underperformed the US Market which returned 7.3% over the past year.
Shareholder returns
| CRBP | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.3% | 3.1% | 1.8% |
| 30 Day | -8.9% | -2.4% | -0.7% |
| 90 Day | -17.5% | -0.8% | 0.06% |
| 1 Year | -31.2%-31.2% | -7.1%-7.9% | 9.7%7.3% |
| 3 Year | -44.2%-44.2% | 14.2%10.3% | 46.3%36.9% |
| 5 Year | n/a | 0.07%-4.8% | 64.5%46.5% |
Price Volatility Vs. Market
How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
How Does Investing In Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Impact The Volatility Of Your Portfolio?3 weeks ago | Simply Wall St
Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Salary Reflect Performance?1 month ago | Simply Wall St
What Percentage Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Do Insiders Own?Valuation
Is Corbus Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?
6.81x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: CRBP ($4.99) is trading above our estimate of fair value ($1.29)
Significantly Undervalued: CRBP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRBP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CRBP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate CRBP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRBP is overvalued based on its PB Ratio (6.8x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
42.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBP's revenue (70.7% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: CRBP's revenue (70.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Corbus Pharmaceuticals Holdings performed over the past 5 years?
-52.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of -52.4% per year.
Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).
Return on Equity
High ROE: CRBP has a negative Return on Equity (-118.19%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: CRBP is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: CRBP is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Corbus Pharmaceuticals Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CRBP's short term assets ($75.4M) exceeds its short term liabilities ($29.4M)
Long Term Liabilities: CRBP's short term assets (75.4M) exceeds its long term liabilities (7.3M)
Debt to Equity History and Analysis
Debt Level: CRBP's debt to equity ratio (0.2%) is considered satisfactory
Reducing Debt: CRBP's debt to equity ratio has reduced from 8.5% to 0.2% over the past 5 years.
Balance Sheet
Inventory Level: CRBP has a low level of unsold assets or inventory.
Debt Coverage by Assets: CRBP's debt is covered by short term assets (assets are 758.970960x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CRBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29% each year
Next Steps
Dividend
What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate CRBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CRBP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CRBP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRBP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Corbus Pharmaceuticals Holdings's salary, the management and board of directors tenure and is there insider trading?
5.2yrs
Average management tenure
CEO
Yuval Cohen (44yo)
5.5yrs
Tenure
US$3,572,460
Compensation
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc ...
CEO Compensation Analysis
Compensation vs. Market: Yuval's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
5.2yrs
Average Tenure
61yo
Average Age
Experienced Management: CRBP's management team is seasoned and experienced (5.2 years average tenure).
Board Age and Tenure
4.4yrs
Average Tenure
47yo
Average Age
Experienced Board: CRBP's board of directors are considered experienced (4.4 years average tenure).
Insider Trading
Insider Buying: CRBP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 1,500 |
| Max Price | US$5.48 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 1,639 |
| Max Price | US$6.10 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 1,500 |
| Max Price | US$6.00 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 1,175 |
| Max Price | US$6.06 |
| Entity | Individual |
| Role | Chief Operating Officer Chief Operating Officer |
| Shares | 15,000 |
| Max Price | US$5.86 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 1,389 |
| Max Price | US$7.20 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 1,000 |
| Max Price | US$7.23 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 100 |
| Max Price | US$7.12 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 995 |
| Max Price | US$6.99 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 2,000 |
| Max Price | US$6.98 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 1,000 |
| Max Price | US$6.98 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 5,000 |
| Max Price | US$6.85 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 4,638 |
| Max Price | US$6.47 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 1,500 |
| Max Price | US$6.67 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 1,530 |
| Max Price | US$6.49 |
Ownership Breakdown
Management Team
Sean Moran (61yo)
Chief Financial Officer
- Tenure: 5.5yrs
- Compensation: US$1.24m
Mark Tepper (62yo)
Co-Founder & Consultant
- Tenure: 0.5yrs
- Compensation: US$1.66m
Yuval Cohen (44yo)
CEO & Director
- Tenure: 5.5yrs
- Compensation: US$3.57m
Barbara White (69yo)
Chief Medical Officer
- Tenure: 5.2yrs
- Compensation: US$1.69m
Craig Millian (51yo)
Chief Commercial Officer
- Tenure: 0.7yrs
Scott Constantine
Senior Director & Head of Clinical Operations
- Tenure: 0yrs
Robert Discordia
Chief Operating Officer
- Tenure: 0yrs
Ted Jenkins
Senior Director of Investor Relations & Communications
- Tenure: 0yrs
Sergei Atamas
Executive Director of Research
- Tenure: 0yrs
Board Members
Chip Catlin (71yo)
Director
- Tenure: 5.2yrs
- Compensation: US$213.62k
David Hochman (44yo)
Director
- Tenure: 5.8yrs
- Compensation: US$205.20k
Alan Holmer (69yo)
Chairman
- Tenure: 5.5yrs
- Compensation: US$238.71k
Yuval Cohen (44yo)
CEO & Director
- Tenure: 5.5yrs
- Compensation: US$3.57m
Charles Serhan
Member of Scientific Advisory Board
- Tenure: 4.4yrs
George Kunos
Member of Scientific Advisory Board
- Tenure: 1.1yrs
Paris Panayiotopoulos (45yo)
Director
- Tenure: 2yrs
- Compensation: US$215.96k
Michael Knowles
Member of Scientific Advisory Board
- Tenure: 0yrs
John Jenkins (61yo)
Director
- Tenure: 1.3yrs
- Compensation: US$325.35k
Rachelle Jacques (47yo)
Director
- Tenure: 0.5yrs
Company Information
Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Corbus Pharmaceuticals Holdings, Inc.
- Ticker: CRBP
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$322.611m
- Shares outstanding: 64.65m
- Website: https://www.corbuspharma.com
Number of Employees
Location
- Corbus Pharmaceuticals Holdings, Inc.
- 500 River Ridge Drive
- Norwood
- Massachusetts
- 2062
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRBP | NasdaqGM (Nasdaq Global Market) | Yes | New Common Shares | US | USD | Oct 2014 |
| 337 | DB (Deutsche Boerse AG) | Yes | New Common Shares | DE | EUR | Oct 2014 |
| 0SZI | LSE (London Stock Exchange) | Yes | New Common Shares | GB | USD | Oct 2014 |
Biography
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 00:37 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.